Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors

Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors

The carcinoembryonic antigen glypican-3 (GPC3) is a good target of anticancer immunotherapy against pediatric solid tumors expressing GPC3. In this non-randomized, open-label, phase I clinical trial, we analyzed the safety and efficacy of GPC3-peptide vaccination in patients with pediatric solid tum...

Full description

Bibliographic Details
Main Authors: Nobuhiro Tsuchiya, Ako Hosono, Toshiaki Yoshikawa, Kayoko Shoda, Kazuto Nosaka, Manami Shimomura, Junichi Hara, Chika Nitani, Atsushi Manabe, Hiroki Yoshihara, Yosuke Hosoya, Hide Kaneda, Yoshiaki Kinoshita, Kenichi Kohashi, Kenichi Yoshimura, Norihiro Fujinami, Keigo Saito, Shoichi Mizuno, Tetsuya Nakatsura
Format: Article
Language:English
Published: Taylor & Francis Group 2018-01-01
Series:OncoImmunology
Subjects:
peptide vaccine
glypican-3 (gpc3)
ctl
pediatric solid tumors
phase i
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1377872

Internet

http://dx.doi.org/10.1080/2162402X.2017.1377872

Similar Items